Pregnancy is a critical period where the toxic risk of anticoagulant drugs is important for women and also for early embryo and fetus.
During pregnancy, VKA could cause maternal outcome such as maternal hemorrhages, systemic thromboembolism or prosthetic valve failure.
In different cohort studies [, , ], teratogenicity rate (structural congenital anomalies) of warfarin was evaluated at 5.0 % (2,4%–10,5 % depending on the study) for treatment doses between 3 mg/day to 16,5 mg/day. The highest risk of teratogenicity was found between 6–9 weeks of pregnancy with a stronger effect during the 8th week of pregnancy at 5 mg/day of warfarin .
Glasp is a social web highlighter that people can highlight and organize quotes and thoughts from the web, and access other like-minded people’s learning.